• Akari Therapeutics will present its RNA-splicing antibody-drug conjugate payload strategy at the 3rd Annual ADC Payload Summit, November 4-6, 2026, in Boston.
• Oncology head Satyajit Mitra will present November 6 at 3:00 p.m. ET, covering mechanisms combining cancer-cell killing with immune activation.
• The presentation will examine preclinical findings supporting PH1, the payload underlying lead candidate AKTX-101, a TROP2-targeting antibody-drug conjugate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300905PRIMZONEFULLFEED9856712) on October 30, 2026, and is solely responsible for the information contained therein.